Uterine fibroid

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022

Retrieved on: 
Thursday, May 19, 2022
SIX Swiss Exchange, Birth certificate, Uterine fibroid, Director, NASDAQ, Nasdaq, Endometriosis, AGM, Investor, Consolidated, Annual report, Board, Annual general meeting, Drug development, The Annual Report, Statute, Renewable energy

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    Geneva, Switzerland May 19, 2022 ObsEva SA(NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced that shareholders approved all Board proposals at its 2022 Annual General Meeting held on May 18, 2022.
  • To access the general meetings section of the Companys website, please click here.
  • To access the AGM 2022 section of the general meetings section directly, please click here.
  • ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens health.

ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

Retrieved on: 
Thursday, May 19, 2022
SIX Swiss Exchange, Royal commission, GSK, U.S. Securities and Exchange Commission, Birth certificate, Risk, University of Bath, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Uterine fibroid, Food, Chair, Â, European Commission, Director, European Medicines Agency, Annual, New Drug Application, Woman, NASDAQ, Coronavirus, Nasdaq, Endometriosis, Investor, Pharmacology, Research, FDA, Retirement, Board, Bachelor of Science, GlaxoSmithKline, Annual general meeting, Drug development, Report, Senior advisor, SEC, Growth, Drug discovery, Security (finance), American Management Association, CEO, Pharmaceutical industry

Ms. Clancy has served as a member of ObsEvas Board of Directors since 2013 and was previously Chair from November 2013 to December 2016.

Key Points: 
  • Ms. Clancy has served as a member of ObsEvas Board of Directors since 2013 and was previously Chair from November 2013 to December 2016.
  • Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting.
  • I would also like to sincerely thank Frank for his years of Board contribution.
  • The tremendous progress across the pipeline, which positions ObsEva for upcoming milestones, is a testament to Franks Board leadership.

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Retrieved on: 
Wednesday, May 18, 2022
Company, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Uterine fibroid, Hyperthermia, National Medical Products Administration, Hematuria, MRI, BPH, Bone, CE, PricewaterhouseCoopers, Humanitarian Device Exemption, FDA, Prostate cancer, Technology, Risk, Health Canada, Remuneration, Phrase, Growth, Urethra, Rectum, Pharmaceutical industry, Medical imaging, Profound Pharma

Detailed voting results for all resolutions will be posted under the Companys profile at www.sedar.com .

Key Points: 
  • Detailed voting results for all resolutions will be posted under the Companys profile at www.sedar.com .
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Profound Medical Clarifies Recent Insider Buying

Retrieved on: 
Wednesday, May 18, 2022
Company, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Form 4, Uterine fibroid, Hyperthermia, Hematuria, U.S. Securities and Exchange Commission, Beneficial ownership, Nasdaq, National Medical Products Administration, MRI, NASDAQ, BPH, Bone, CE, TSX, FDA, Humanitarian Device Exemption, Prostate cancer, Technology, The Insider, Risk, Health Canada, Phrase, Growth, Urethra, Rectum, GLOBE, Pharmaceutical industry, Security (finance), Profound Pharma

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) today provided the following clarifications.

Key Points: 
  • TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) today provided the following clarifications.
  • This information is being provided solely to assist the Companys shareholders in the present circumstances, and Profound does not intend to issue further press releases regarding insider transactions.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

TULSA-PRO® Was Front and Center at AUA2022

Retrieved on: 
Tuesday, May 17, 2022
Department, Physician, Education, Software, University of Texas Southwestern Medical Center, Company, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Uterine fibroid, Hyperthermia, American Urological Association, Hematuria, National Medical Products Administration, Susceptibility weighted imaging, Patient, MRI, SWI, NASDAQ, ADC, BPH, Bone, Quality of life, Prostate, AMA, Benign prostatic hyperplasia, CE, Trial of the century, TSX, Humanitarian Device Exemption, DWI, FDA, Urology, Prostate cancer, AUA, Man, University, Technology, Risk, LUTS, Rectum, Diffusion, Health Canada, Plenary session, Turku University, Phrase, Growth, Urethra, Medical Corps (United States Army), GLOBE, Medical imaging, Pharmaceutical industry, Profound Pharma

Of particular note, Kenneth A. Goldberg, M.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, performed a Semi-Live TULSA Procedure during the afternoon Plenary Session on May 13th.

Key Points: 
  • Of particular note, Kenneth A. Goldberg, M.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, performed a Semi-Live TULSA Procedure during the afternoon Plenary Session on May 13th.
  • We are extremely encouraged by the positive feedback we received at this event, which adds to the momentum of Profounds ongoing commercialization strategy for TULSA-PRO.
  • The study reported 6-month improvement in patient quality of life, LUTS, sexual function and uroflowmetry, with all men discontinuing their BPH medication.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

Retrieved on: 
Monday, May 16, 2022
SIX Swiss Exchange, Birth certificate, Account manager, Uterine fibroid, Webcast, NASDAQ, Nasdaq, Endometriosis, EST, Conference, Pregnancy, Drug development, Pharmaceutical industry

GENEVA, Switzerland May 16, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 26, 2022.

Key Points: 
  • GENEVA, Switzerland May 16, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 26, 2022.
  • The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 10:30 a.m. EST on Tuesday, May 24, 2022.
  • A webcast can be accessed here and will also be accessible under Events Calendar in the investors section of ObsEvas website.
  • ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.

ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

Retrieved on: 
Thursday, May 12, 2022
SIX Swiss Exchange, Drug development, NASDAQ, Telephone, Birth certificate, Nasdaq, Endometriosis, Uterine fibroid, Webcast, Pharmaceutical industry

ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.

Key Points: 
  • ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
  • Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576.
  • The webcast can be accessed live here and will also be accessible under Events Calendar in the investors section of ObsEvas website .
  • The webcast will be archived on the companys website for at least 30 days after the conference call.

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

Retrieved on: 
Monday, May 9, 2022
LHRH, European Economic Area, Endometriosis, Female, SEC, Royal commission, Twitter, Woman, Prostate, NYSE, European Commission, Patient, Partnership, Risk, FDA, Sidley Austin, Regulation of tobacco by the U.S. Food and Drug Administration, New Drug Application, LinkedIn, Uterine fibroid, Roivant Sciences, Private Securities Litigation Reform Act, Urban economics, Pregnancy, Gonadotropin-releasing hormone, Injection, Infertility, Prostate cancer, Cyprus Securities and Exchange Commission, Medicines and Healthcare products Regulatory Agency, Growth, Man, Calendar, GLOBE, MHRA, Food, Radiation, Testosterone, Cancer, Adult, EC, Pharmaceutical industry, Medical imaging, Accord

We are proud to launch ORGOVYX in Europe, as an addition to our specialty brand offerings, said Binish Chudgar, Managing Director of Accord.

Key Points: 
  • We are proud to launch ORGOVYX in Europe, as an addition to our specialty brand offerings, said Binish Chudgar, Managing Director of Accord.
  • Accord currently supplies around 1 in 3 injectable oncology medicines in Europe and this agreement underpins our commitment to patients with cancer and our continued investment in novel therapies.
  • With over 1.9 million men living with prostate cancer in Europe, our partnership with Myovant will provide men living with hormone-sensitive advanced prostate cancer a new oral treatment option.
  • ORGOVYX (relugolix, 120 mg) is indicated in Europe for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

Retrieved on: 
Monday, May 2, 2022
Board, SIX Swiss Exchange, Drug development, Teva Pharmaceuticals, Private Securities Litigation Reform Act, University, Woman, NASDAQ, European Medicines Agency, Company, NYSE, Food, Â, Birth certificate, European Commission, Adolescence, Security (finance), Coronavirus, FDA, Risk, Georgia State University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Pleasure, Endometriosis, Leadership, New Drug Application, Investor, Nasdaq, SEC, CEO, Research, Head, Medical College of Georgia, TEVA, Medical college, Uterine fibroid, Royal commission, Medicine, Pharmaceutical industry, Science, Global, Nursing, Maternal–fetal medicine

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland May 2, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the companys Executive Committee, effective May 9, 2022.
  • Dr. Howard, who brings to ObsEva more than 20 years of womens health expertise, will be responsible for the Company's clinical development and medical affairs strategy.
  • Brandi is the clear and unanimous choice of the Board and executive team to serve as our Chief Clinical Officer, given her demonstrated success leading clinical development programs, medical affairs organizations, new product launches, and regulatory processes.
  • Dr. Howard has deep womens health expertise with increasing responsibilities in medical affairs strategy and leadership, as well as leading large clinical development programs.

La Jolla Vein & Vascular Expands Services and Announces New Medical Staff

Retrieved on: 
Tuesday, April 26, 2022
Radiology, Hospitals, Health, Other Health, National Association Medical Staff Services, Family, University, GAE, Uterine fibroid, Varicose veins, Woman, Varicocele, General surgery, Pelvic congestion syndrome, Diagnosis, List, Angioplasty, Osteoarthritis, Interventional radiology, Vascular disease, Deep vein thrombosis, University of California, Moyamoya disease, Health, May–Thurner syndrome, School, USC, De Young, Medical school, Degenerative disease, Multimedia, Medical imaging, Psychology

La Jolla Vein & Vascular (LJVV), the regional leader in vein treatment, is excited to announce expanded vascular services, including endovascular procedures that rely on advanced medical imaging in real-time.

Key Points: 
  • La Jolla Vein & Vascular (LJVV), the regional leader in vein treatment, is excited to announce expanded vascular services, including endovascular procedures that rely on advanced medical imaging in real-time.
  • View the full release here: https://www.businesswire.com/news/home/20220426005279/en/
    Dr. Elliot DeYoung, Interventional Radiologist joins medical staff at La Jolla Vein & Vascular (Photo: Business Wire)
    Now spanning four locations, LJVV is better positioned to provide expert care for increasingly complex vascular conditions throughout Southern California.
  • Previously known as La Jolla Vein Care, the new LJVV name reflects the expanded service offering.
  • About La Jolla Vein & Vascular:
    La Jolla Vein & Vascular is San Diegos most comprehensive endovascular center, dedicated exclusively to the diagnosis and treatment of vascular disorders.